Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL577863 | 1.00 | KMT2A (0.46) | KMT2ACYP2D6CHRNA7HSD11B1ALDH1A1 | |
| SCHEMBL577083 | 1.00 | KMT2A (0.46) | KMT2ACYP2D6CHRNA7HSD11B1ALDH1A1 | |
| SCHEMBL19679817 | 1.00 | KMT2A (0.46) | KMT2ACYP2D6CHRNA7HSD11B1ALDH1A1 | |
| SCHEMBL19679818 | 1.00 | KMT2A (0.46) | KMT2ACYP2D6CHRNA7HSD11B1ALDH1A1 | |
| SCHEMBL19679814 | 1.00 | KMT2A (0.46) | KMT2ACYP2D6CHRNA7HSD11B1ALDH1A1 | |
| SCHEMBL2759514 | 1.00 | KMT2A (0.46) | KMT2ACYP2D6CHRNA7HSD11B1ALDH1A1 | |
| SCHEMBL1044668 | 1.00 | KMT2A (0.46) | KMT2ACYP2D6CHRNA7HSD11B1ALDH1A1 | |
| SCHEMBL48580 | 0.96 | — | — | |
| SCHEMBL1093603 | 0.96 | — | — | |
| SCHEMBL1043052 | 0.96 | CYP2D6 (0.48) | KMT2ACYP2D6CHRNA7HSD11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017706-B2 | Process for production of polymers with iron complex catalyst | DIC CORPORATION (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20110105703-A1 | PROCESS FOR PRODUCTION OF POLYMERS WITH IRON COMPLEX CATALYST | DIC Corporatio (JP) | 2011-05-05 | — | — | US | disclosed |
| EP-2269995-A1 | PROCESS FOR PRODUCTION OF POLYMERS WITH IRON COMPLEX CATALYST | DIC Corporation (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105703-A1 | PROCESS FOR PRODUCTION OF POLYMERS WITH IRON COMPLEX CATALYST | TFRC, FECH, FTH1 | KMT2A 2515/4885CYP2D6 1882/4885CHRNA7 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.